https://azuraophthalmics.com/press-releases/azura-ophthalmics-receives-16-million-in-series-b-funding-to-develop-treatment-for-leading-cause-of-dry-eye-disease/ 2022-09-01T05:30:17+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-raises-us20-million-for-registration-studies-for-treatment-of-leading-cause-of-dry-eye-disease/ 2022-09-01T05:21:46+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-primary-endpoints-met-in-topline-results-from-phase-2-trial-of-the-companys-investigational-treatment-for-contact-lens-discomfort/ 2022-09-01T05:17:45+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-meibomian-gland-dysfunction/ 2022-09-01T05:16:20+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-appoints-biopharma-industry-veteran-steven-altschuler-m-d-as-chair-of-the-board/ 2022-09-01T05:16:45+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-secures-grant-to-evaluate-azr-md-001-for-improved-vision-quality-related-to-contact-lens-discomfort/ 2022-09-10T00:37:57+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-formation-of-scientific-advisory-board-sab/ 2022-09-21T12:58:57+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-provides-update-on-azr-md-001-phase-2-clinical-program-targeting-meibomian-gland-dysfunction/ 2022-09-28T12:38:29+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-u-s-and-european-patents/ 2022-10-19T20:26:08+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/ 2022-11-17T12:02:42+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-participation-at-upcoming-investor-conferences/ 2022-11-21T13:42:11+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-presents-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction-at-ophthalmology-innovation-summit-xii/ 2022-12-09T13:09:48+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-participation-at-the-2023-svb-securities-global-biopharma-conference/ 2023-01-17T21:59:18+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-american-society-of-cataract-and-refractive-surgery-and-association-for-research-in-vision-and-ophthalmology-annua/ 2023-04-20T13:41:23+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/ 2023-12-18T21:18:12+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/ 2024-03-28T22:44:00+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-announces-enrollment-of-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-meibomian-gland-dysfunction/ 2024-06-04T13:46:09+00:00 monthly 0.2 https://azuraophthalmics.com/press-releases/azura-ophthalmics-corporate-update-azr-md-001-nda-submission-expected-in-2h-2026/ 2025-12-10T13:38:21+00:00 monthly 0.2